论文部分内容阅读
目的探讨MRI扩散加权成像在乳腺浸润性导管癌新辅助化疗(NAC)疗效评价中的作用。方法 30例乳腺浸润性导管癌患者,术前NAC治疗前后均行MRI常规扫描及扩散加权成像检查。由两位有经验的影像医师独立分析对比NAC治疗前后肿瘤最大径及表观扩散系数(ADC)的变化。采用配对t检验分析肿瘤最大径及ADC值变化。结果乳腺浸润性导管癌NAC治疗前的肿瘤最大径为(4.33±0.83)cm,治疗后为(2.04±0.64)cm,其肿瘤最大径明显缩小(P<0.001)。b=1 000时,NAC治疗前后肿瘤平均ADC值分别为(1.89±0.15)×10-3mm2/s和(1.14±0.31)×10-3mm2/s,NAC治疗后病灶ADC值减小(P<0.05)。结论 MRI扩散加权成像可无创并准确地评价NAC的治疗效果,有助于疗效评价和手术决策。
Objective To investigate the role of MRI diffusion weighted imaging in the evaluation of the efficacy of neoadjuvant chemotherapy (NAC) in invasive ductal carcinoma of the breast. Methods Thirty patients with invasive ductal carcinoma of the breast were examined by conventional MRI and diffusion weighted imaging before and after NAC. Two experienced imaging physicians independently analyzed the changes in maximum diameter and apparent diffusion coefficient (ADC) before and after NAC treatment. Paired t test was used to analyze the maximum diameter of tumor and ADC value. Results The maximum tumor diameter of breast invasive ductal carcinoma before NAC was (4.33 ± 0.83) cm and (2.04 ± 0.64) cm after treatment. The maximum diameter of tumor was significantly reduced (P <0.001). The average ADC values of tumor before and after NAC treatment were (1.89 ± 0.15) × 10-3mm2 / s and (1.14 ± 0.31) × 10-3mm2 / s, respectively. 0.05). Conclusion MRI diffusion weighted imaging can be noninvasive and accurately evaluate the therapeutic effect of NAC, which is helpful for the evaluation of efficacy and surgical decision-making.